Brief: Tiziana Announces Positive Clinical Data From A Secondary Progressive Multiple Sclerosis Patient Treated For Six Months With Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody
10/03/2022 12:38
March 10 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA ANNOUNCES POSITIVE CLINICAL DATA FROM A SECONDARY
PROGRESSIVE MULTIPLE SCLEROSIS PATIENT TREATED FOR SIX MONTHS
WITH INTRANASALLY ADMINISTERED FORALUMAB, A FULLY HUMAN ANTI-CD3
MONOCLONAL ANTIBODY
* TIZIANA LIFE SCIENCES LTD - INTRANASAL FORALUMAB WAS
WELL-TOLERATED WITH NO ADVERSE REACTIONS OR LABORATORY
ABNORMALITIES
* TIZIANA LIFE SCIENCES LTD - DATA SHOW SUSTAINED INHIBITION
OF
MICROGLIAL ACTIVATION AS ASSESSED BY POSITRON EMISSION
TOMOGRAPHY
* TIZIANA LIFE SCIENCES LTD - FDA HAS ALLOWED A SECOND
PATIENT TO
RECEIVE INTRANASAL FORALUMAB THERAPY UNDER A SEPARATE
SINGLE-PATIENT EXPANDED ACCESS IND
Source text for Eikon: ID:nGNX45fNZs
Further company coverage: TLSA.O
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis